+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Elite Pharmaceuticals Inc (ELTP) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 51 Pages
  • September 2023
  • GlobalData
  • ID: 1314949
Elite Pharmaceuticals Inc (ELTP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Elite Pharmaceuticals Inc (Elite) is a specialty pharmaceutical company that focuses on the development of oral sustained and controlled release drug products. The company manufactures and develops generic drugs upon marketing approvals via Abbreviated New Drug Applications (ANDA) and branded drugs via New Drug Application (NDA) for the treatment of cardiovascular disorders, allergies, infections, bariatric and others. Its key commercialized product portfolio include Adipex-P, Bontril for Bariatric therapy; Revia for Pain related; Dantrium for muscle relaxation; Adderall XR for central nervous system; Loxapine for Antipsychotic; among others. Elite also has a pipeline of abuse-deterrent opioids for the treatment of chronic pain. The company uses its proprietary ART (abuse-deterrent technology) platform to develop and manufacture oral, controlled-release drugs. Elite is headquartered in Northvale, New Jersey, the US.

Elite Pharmaceuticals Inc Key Recent Developments

  • Sep 25, 2023: Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
  • Aug 28, 2023: Back to NewsroomBack to Newsroom Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
  • Aug 14, 2023: Elite Pharmaceuticals, Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
  • Feb 15, 2023: Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Elite Pharmaceuticals Inc - Key Facts
  • Elite Pharmaceuticals Inc - Key Employees
  • Elite Pharmaceuticals Inc - Key Employee Biographies
  • Elite Pharmaceuticals Inc - Major Products and Services
  • Elite Pharmaceuticals Inc - History
  • Elite Pharmaceuticals Inc - Company Statement
  • Elite Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Elite Pharmaceuticals Inc - Business Description
  • Other Break-up: Licensing fees
  • Performance
  • Other Break-up: Manufacturing fees
  • Performance
  • Business Segment: Branded Pharmaceuticals
  • Overview
  • Business Segment: Generic Pharmaceuticals
  • Overview
  • Performance
  • R&D Overview
  • Elite Pharmaceuticals Inc - Corporate Strategy
  • Elite Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Elite Pharmaceuticals Inc - Strengths
  • Elite Pharmaceuticals Inc - Weaknesses
  • Elite Pharmaceuticals Inc - Opportunities
  • Elite Pharmaceuticals Inc - Threats
  • Elite Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Elite Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 25, 2023: Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
  • Aug 28, 2023: Back to NewsroomBack to Newsroom Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
  • Aug 14, 2023: Elite Pharmaceuticals, Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
  • Feb 15, 2023: Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information
  • Dec 22, 2022: Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist
  • Aug 11, 2022: Elite Pharmaceuticals to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2023 Financial Results on August 16, 2022
  • Jun 29, 2022: Elite Pharmaceuticals Reports Financial Results for the Fiscal Year Ended March 31 2022 and Provides Conference Call Information
  • Jun 23, 2022: Elite Pharmaceuticals to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2022 Financial Results on June 30, 2022
  • May 11, 2022: Elite Pharmaceuticals Appoints Robert Chen as Chief Financial Officer
  • Feb 09, 2022: Elite Pharmaceuticals to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2022 Financial Results on February 15, 2022
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Elite Pharmaceuticals Inc, Key Facts
  • Elite Pharmaceuticals Inc, Key Employees
  • Elite Pharmaceuticals Inc, Key Employee Biographies
  • Elite Pharmaceuticals Inc, Major Products and Services
  • Elite Pharmaceuticals Inc, History
  • Elite Pharmaceuticals Inc, Subsidiaries
  • Elite Pharmaceuticals Inc, Key Competitors
  • Elite Pharmaceuticals Inc, Ratios based on current share price
  • Elite Pharmaceuticals Inc, Annual Ratios
  • Elite Pharmaceuticals Inc, Interim Ratios
  • Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Elite Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Elite Pharmaceuticals Inc, Performance Chart (2019 - 2023)
  • Elite Pharmaceuticals Inc, Ratio Charts
  • Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Elite Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Mylan Laboratories Ltd
  • Mallinckrodt LLC
  • Collegium Pharmaceutical Inc
  • Aurobindo Pharma USA Inc
  • Sandoz Inc
  • Teva Pharmaceuticals USA Inc
  • Purdue Pharma LP
  • Endo Pharmaceuticals Inc
  • Acura Pharmaceuticals Inc
  • Pfizer Inc